头颈部鳞状细胞癌化疗作用的最新进展
Update on role of chemotherapy in head and neck squamous cell cancer.
作者信息
Marur S, Forastiere A A
机构信息
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein CRB1 G92 1650 Orleans Street, Baltimore, MD 21231-1000 USA.
出版信息
Indian J Surg Oncol. 2010 Apr;1(2):85-95. doi: 10.1007/s13193-010-0021-y. Epub 2010 Nov 21.
Abstract
Head and neck squamous cell cancer (HNSCC) is most commonly a tobacco-related disease, affecting nearly 600,000 people worldwide each year. For decades, HNSCC has been treated successfully with multimodality treatments including, surgery, radiation, and chemotherapy, though the 'perfect' treatment paradigm remains elusive. This review will discuss a number of clinical trials, comparing various combinations of chemotherapy and the settings in which they are most successful. Promising research and recent data on the combination of cytotoxic chemotherapy with new biological agents indicate chemotherapy plays a critical role in treatment of HNSCC and will only continue to improve.
摘要
头颈部鳞状细胞癌（HNSCC）最常见的是一种与烟草相关的疾病，每年在全球影响近60万人。几十年来，HNSCC一直通过包括手术、放疗和化疗在内的多模式治疗成功治愈，尽管“完美”的治疗模式仍然难以捉摸。本综述将讨论一些临床试验，比较化疗的各种组合及其最成功的应用场景。关于细胞毒性化疗与新型生物制剂联合应用的有前景的研究和最新数据表明，化疗在HNSCC的治疗中起着关键作用，并且只会不断改善。
相似文献
1
Update on role of chemotherapy in head and neck squamous cell cancer.头颈部鳞状细胞癌化疗作用的最新进展
Indian J Surg Oncol. 2010 Apr;1(2):85-95. doi: 10.1007/s13193-010-0021-y. Epub 2010 Nov 21.
2
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.含西妥昔单抗的联合方案用于局部晚期及复发或转移性头颈部鳞状细胞癌
Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019.
3
Pharmacotherapy of head and neck squamous cell carcinoma.头颈部鳞状细胞癌的药物治疗
Expert Opin Pharmacother. 2009 Oct;10(14):2291-302. doi: 10.1517/14656560903136754.
4
Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.诱导化疗联合同期放化疗治疗局部晚期头颈部癌患者的毒性谱和临床结局。
Oncol Rep. 2012 Feb;27(2):467-74. doi: 10.3892/or.2011.1512. Epub 2011 Oct 21.
5
Pharmacotherapy of head and neck cancer.头颈癌的药物治疗
Expert Opin Pharmacother. 2015;16(16):2409-22. doi: 10.1517/14656566.2015.1085507. Epub 2015 Oct 29.
6
Molecular targets in squamous cell carcinoma of the head and neck.头颈部鳞状细胞癌的分子靶点
Curr Treat Options Oncol. 2007 Jun;8(3):239-51. doi: 10.1007/s11864-007-0030-4.
7
Integration of molecular targeted therapy with radiation in head and neck cancer.头颈部肿瘤的分子靶向治疗与放疗的整合。
Pharmacol Ther. 2014 Apr;142(1):88-98. doi: 10.1016/j.pharmthera.2013.11.007. Epub 2013 Nov 23.
8
Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.头颈部鳞状细胞癌的全身治疗：历史回顾与近期突破
Laryngoscope. 2017 Nov;127(11):2565-2569. doi: 10.1002/lary.26629. Epub 2017 Jun 5.
9
Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.程序性细胞死亡受体 1（PD-1）抑制剂联合同期放化疗治疗复发性/转移性头颈部鳞状细胞癌患者的协同作用的初步分析。
Radiat Oncol. 2023 Jul 4;18(1):109. doi: 10.1186/s13014-023-02310-8.
10
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.一项随机2期试验的最终结果：研究西妥昔单抗联合诱导化疗及加速或超分割放化疗用于局部晚期头颈癌的疗效
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7.
引用本文的文献
1
Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.药理学抑制 MYC 以减轻鳞状细胞癌临床前模型中的化疗耐药性。
Theranostics. 2024 Jan 1;14(2):622-639. doi: 10.7150/thno.88759. eCollection 2024.
2
Systemic Effects of Radiotherapy and Concurrent Chemo-Radiotherapy in Head and Neck Cancer Patients-Comparison of Serum Metabolome Profiles.头颈部癌患者放疗及同步放化疗的全身效应——血清代谢组学图谱比较
Metabolites. 2020 Feb 7;10(2):60. doi: 10.3390/metabo10020060.
3
Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence.尼妥珠单抗治疗不可切除、复发和/或转移性头颈部鳞状细胞癌的疗效与安全性：一项基于医院的回顾性证据
South Asian J Cancer. 2018 Jul-Sep;7(3):188-192. doi: 10.4103/sajc.sajc_87_18.
4
Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma.头颈部鳞状细胞癌切缘无肿瘤的治疗意义
Oncotarget. 2017 Sep 16;8(48):84320-84328. doi: 10.18632/oncotarget.21035. eCollection 2017 Oct 13.
5
Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.顺铂可诱导头颈部癌中的Bmi-1表达并增加其干细胞比例。
Neoplasia. 2014 Feb;16(2):137-46. doi: 10.1593/neo.131744.
6
The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model.化学预防和临床应用的姜黄素增敏剂可使 HPV（-）但不能使 HPV（+）头颈部鳞状细胞癌对电离辐射敏感，在体外和小鼠原位模型中均如此。
Cancer Biol Ther. 2012 May;13(7):575-84. doi: 10.4161/cbt.19772. Epub 2012 May 1.
本文引用的文献
1
Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).诱导使用西妥昔单抗、紫杉醇和卡铂，随后对 III/IV 期头颈部鳞状癌进行西妥昔单抗、紫杉醇和卡铂同步放化疗：一项 II 期 ECOG-ACRIN 试验（E2303）。
Ann Oncol. 2014 Oct;25(10):2036-2041. doi: 10.1093/annonc/mdu248. Epub 2014 Jul 9.
2
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.头颈部鳞状细胞癌与人乳头瘤病毒：2008年11月9日至10日于华盛顿特区召开的美国国立癌症研究所科学现状会议总结
Head Neck. 2009 Nov;31(11):1393-422. doi: 10.1002/hed.21269.
3
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.头颈部癌化疗的荟萃分析（MACH-NC）：93项随机试验及17346例患者的最新情况
Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.
4
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.顺铂和5-氟尿嘧啶联合或不联合多西他赛进行诱导化疗以保留喉功能的随机试验。
J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. doi: 10.1093/jnci/djp007. Epub 2009 Mar 24.
5
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.厄洛替尼与贝伐单抗用于复发性或转移性头颈部鳞状细胞癌患者：一项I/II期研究
Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7.
6
Seduction by induction?诱导诱惑？
J Clin Oncol. 2009 Jan 1;27(1):9-10. doi: 10.1200/JCO.2008.19.5875. Epub 2008 Dec 1.
7
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.分子靶向药物治疗头颈部复发性或转移性鳞状细胞癌
Hematol Oncol Clin North Am. 2008 Dec;22(6):1209-20, ix. doi: 10.1016/j.hoc.2008.08.002.
8
Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options.优化头颈癌治疗方法。转移性头颈癌：新的选择。
Ann Oncol. 2008 Sep;19 Suppl 7:vii200-3. doi: 10.1093/annonc/mdn456.
9
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.一项关于在氟尿嘧啶和羟基脲基础上的同步放化疗中加入贝伐单抗用于预后不良头颈癌的I期研究。
J Clin Oncol. 2008 Apr 1;26(10):1732-41. doi: 10.1200/JCO.2007.13.1706.
10
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.在一项前瞻性临床试验中，人乳头瘤病毒阳性头颈部鳞状细胞癌患者的生存率提高。
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9. doi: 10.1093/jnci/djn011. Epub 2008 Feb 12.
Zotero 插件